INS and schizophrenia: Further development of our comprehension of anhedonia and its state and trait aspects as well as its relation to insulin signaling and their interlinks are necessary to improve functional outcomes in not only MDD, but also in subjects with chronic pain, substance use disorders, schizophrenia, and Parkinson’s disease.